{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Therriault J"],"funding":["NIA NIH HHS","European Union Joint Program for Neurodegenerative Disorders","Swedish Research Council","Hjärnfonden, Sweden","Swedish Alzheimer Foundation","Weston Brain Foundation","Canadian Institutes of Health Research","Alzheimer’s Association","Alzheimer Drug Discovery Foundation (ADDF), USA","European Research Council","Fonds de Recherche du Québec–Santé","UK Dementia Research Institute","Swedish government and the County Councils, the ALF-agreement","Swedish State Support for Clinical Research"],"pagination":["fcab136"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8249102"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(3)"],"pubmed_abstract":["Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive decline. <i>In vivo</i> biomarkers for Alzheimer's disease are expensive, invasive and inaccessible, yet are critical for accurate disease diagnosis and patient management. Recent ultrasensitive methods to measure plasma phosphorylated tau 181 (p-tau181) display strong correlations with tau positron emission tomography, p-tau181 in CSF, and tau pathology at autopsy. The clinical utility of plasma-based p-tau181 biomarkers is unclear. In a longitudinal multicentre observational study, we assessed 1113 non-demented individuals (509 cognitively unimpaired elderly and 604 individuals with mild cognitive impairment) fro"],"journal":["Brain communications"],"pubmed_title":["Association of plasma P-tau181 with memory decline in non-demented adults."],"pmcid":["PMC8249102"],"funding_grant_id":["#681712","JPND2019-466–236","#2018–02532","#201809–2016862","#AF-742881","#ALFGBG-720931","U19 AG024904","#ALFGBG-715986","2020-VICO-279314","#2017–00915","#FO2017-0243","720931","#RDAPB-201809–2016615","681712","MOP-11–51-3","NIRP-12–259245","U01 AG024904","NIRG-12–92090"],"pubmed_authors":["Gauthier S","Saha-Chaudhuri P","Rosa-Neto P","Tissot C","Mathotaarachchi S","Zetterberg H","Ashton NJ","Alzheimer’s Disease Neuroimaging Initiative","Bezgin G","Chamoun M","Pascoal TA","Benedet AL","Therriault J","Karikari TK","Blennow K","Lussier FZ"],"additional_accession":[]},"is_claimable":false,"name":"Association of plasma P-tau181 with memory decline in non-demented adults.","description":"Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive decline. <i>In vivo</i> biomarkers for Alzheimer's disease are expensive, invasive and inaccessible, yet are critical for accurate disease diagnosis and patient management. Recent ultrasensitive methods to measure plasma phosphorylated tau 181 (p-tau181) display strong correlations with tau positron emission tomography, p-tau181 in CSF, and tau pathology at autopsy. The clinical utility of plasma-based p-tau181 biomarkers is unclear. In a longitudinal multicentre observational study, we assessed 1113 non-demented individuals (509 cognitively unimpaired elderly and 604 individuals with mild cognitive impairment) fro","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-07T20:36:17.545Z","creation":"2022-02-10T18:28:27.554Z"},"accession":"S-EPMC8249102","cross_references":{"pubmed":["34222875"],"doi":["10.1093/braincomms/fcab136"]}}